6,692 Shares in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Bought by Fmr LLC

Fmr LLC bought a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,692 shares of the company’s stock, valued at approximately $33,000.

A number of other large investors also recently bought and sold shares of KYTX. Teachers Retirement System of The State of Kentucky raised its stake in shares of Kyverna Therapeutics by 69.7% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 21,410 shares of the company’s stock worth $161,000 after buying an additional 8,796 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Kyverna Therapeutics by 32.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,794 shares of the company’s stock valued at $283,000 after buying an additional 9,300 shares in the last quarter. Skandinaviska Enskilda Banken AB publ increased its position in Kyverna Therapeutics by 55.8% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 26,195 shares of the company’s stock worth $196,000 after purchasing an additional 9,385 shares during the last quarter. Creative Planning purchased a new stake in shares of Kyverna Therapeutics during the 3rd quarter valued at approximately $54,000. Finally, Federated Hermes Inc. acquired a new position in shares of Kyverna Therapeutics in the 2nd quarter valued at $120,000. 18.08% of the stock is owned by institutional investors and hedge funds.

Kyverna Therapeutics Trading Up 1.0 %

Shares of NASDAQ:KYTX opened at $3.96 on Thursday. Kyverna Therapeutics, Inc. has a one year low of $3.63 and a one year high of $35.06. The business’s 50-day simple moving average is $4.87 and its 200 day simple moving average is $6.66.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.01. The business had revenue of $0.01 million for the quarter. On average, analysts expect that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on KYTX. Wells Fargo & Company lowered their price objective on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. UBS Group assumed coverage on Kyverna Therapeutics in a research report on Thursday, October 10th. They set a “buy” rating and a $13.00 price target for the company. RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, October 9th. HC Wainwright lowered their target price on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, November 20th. Finally, Rodman & Renshaw began coverage on shares of Kyverna Therapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $16.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $25.71.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.